Abstract
Targeting nanomedicine to brain tumors is hampered by the heterogeneity of brain tumors and the blood brain barrier. These represent the main reasons of unsuccessful treatments. Nanomedicine based approaches hold promise for improved brain tissue distribution of drugs and delivery of combination therapies. In this review, we describe the recent advancements and latest achievements in the use of nanocarriers, virus and cell-derived nanoparticles for targeted therapy of brain tumors. We provide successful examples of nanomedicine based approaches for direct targeting of receptors expressed in brain tumor cells or modulation of pathways involved in cell survival as well as approaches for indirect targeting of cells in the tumor stroma and immunotherapies. Although the field is at its infancy, clinical trials involving nanomedicine based approaches for brain tumors are ongoing and many others will start in the near future.
Keywords: Nanomedicine, brain tumor, nanoparticles, glioblastoma multiforme, convection enhanced delivery (CED), dendrimers, nanoprodrugs, exosomes, viruses.
Current Pharmaceutical Design
Title:Targeting Nanomedicine to Brain Tumors: Latest Progress and Achievements
Volume: 23 Issue: 13
Author(s): Moniek van ‘t Root, Clemens Löwik and Laura Mezzanotte*
Affiliation:
- Optical Molecular Imaging, Department of Radiology, Erasmus Medical Center, 's-Gravendijkwal 230, 3015 CE Rotterdam,,Netherlands
Keywords: Nanomedicine, brain tumor, nanoparticles, glioblastoma multiforme, convection enhanced delivery (CED), dendrimers, nanoprodrugs, exosomes, viruses.
Abstract: Targeting nanomedicine to brain tumors is hampered by the heterogeneity of brain tumors and the blood brain barrier. These represent the main reasons of unsuccessful treatments. Nanomedicine based approaches hold promise for improved brain tissue distribution of drugs and delivery of combination therapies. In this review, we describe the recent advancements and latest achievements in the use of nanocarriers, virus and cell-derived nanoparticles for targeted therapy of brain tumors. We provide successful examples of nanomedicine based approaches for direct targeting of receptors expressed in brain tumor cells or modulation of pathways involved in cell survival as well as approaches for indirect targeting of cells in the tumor stroma and immunotherapies. Although the field is at its infancy, clinical trials involving nanomedicine based approaches for brain tumors are ongoing and many others will start in the near future.
Export Options
About this article
Cite this article as:
Root van ‘t Moniek , Löwik Clemens and Mezzanotte Laura *, Targeting Nanomedicine to Brain Tumors: Latest Progress and Achievements, Current Pharmaceutical Design 2017; 23 (13) . https://dx.doi.org/10.2174/1381612822666161227153359
DOI https://dx.doi.org/10.2174/1381612822666161227153359 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews Serum Carboxypeptidase N1 Serves as a Potential Biomarker Complementing CA15-3 for Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Nifurtimox Hampered the Progression of Astroglioma <i>In vivo Via</i> Manipulating the AKT-GSK3β axis
Current Molecular Medicine Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma
Current Cancer Therapy Reviews Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology Withdrawal Notice: Circulatory Cells as Tumortropic Carrier for Targetability Improvement
Current Drug Delivery Mesenchymal Stem Cells: A New Generation of Therapeutic Agents as Vehicles in Gene Therapy
Current Gene Therapy Reflecting Back to Bring Nitric Oxide Research to the Laboratory
Current Medicinal Chemistry Involvement of β-arrestin-2 and Clathrin in Agonist-Mediated Internalization of the Human Cannabinoid CB2 Receptor
Current Molecular Pharmacology Ligands Targeting the Excitatory Amino Acid Transporters (EAATs)
Current Topics in Medicinal Chemistry Brain Segmentation Using Deep Neural Networks
International Journal of Sensors, Wireless Communications and Control The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design Recent Development in Fluorescent Probes for Copper Ion Detection
Current Topics in Medicinal Chemistry Liposomes Containing Gadodiamide: Preparation, Physicochemical Characterization, and In Vitro Cytotoxic Evaluation
Current Drug Delivery Oligonucleotide Aptamers for Glioma Targeting: An Update
Central Nervous System Agents in Medicinal Chemistry Development and Current Status of Unconventional Platinum Anticancer Complexes
Mini-Reviews in Medicinal Chemistry Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine
Current Pharmaceutical Design MicroRNA Dysregulation in Gastric Cancer
Current Pharmaceutical Design Role of Gap Junction Channel in the Development of Beat-to-Beat Action Potential Repolarization Variability and Arrhythmias
Current Pharmaceutical Design Proteasome Inhibitors in Cancer Therapy
Current Drug Targets